Rilzabrutinib
- Generic Name
- Rilzabrutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H40FN9O3
- CAS Number
- 1575591-66-0
- Unique Ingredient Identifier
- 5G1WE425BI
- Background
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Principia Biopharma, a Sanofi Company
- Target Recruit Count
- 81
- Registration Number
- NCT03395210
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center Site Number : 1099, Boston, Massachusetts, United States
🇨🇦Investigational Site Number : 1162, Montreal, Quebec, Canada
🇦🇺Investigational Site Number : 103, Perth, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath